The synthesis and functionalization of iron oxide nanoparticles (IONPs) is versatile, which
has enhanced the interest in studying them as theranostic agents over recent years. As …

Brain metastasis (BM), a devastating complication of advanced malignancy, has a high
incidence in non-small cell lung cancer (NSCLC). As novel systemic treatment drugs and …

Introduction According to mechanisms of adaptive immune resistance, tumor immune
microenvironment (TIME) is classified into four types:(1) programmed death-ligand 1 (PD …

Intracortical microelectrodes are a critical component of brain-machine interface (BMI)
systems. The recording performance of intracortical microelectrodes used for both basic …

Background The expression level of the programmed cell death ligand 1 (PD-L1) appears to
be a predictor for response to immunotherapy using checkpoint inhibitors in patients with …

Brain metastases signify a deleterious milestone in the progression of several advanced
cancers, predominantly originating from lung, breast and melanoma malignancies, with a …

Amplification of fibroblast growth factor receptor 1 (FGFR1) in non-small cell lung cancer
(NSCLC) has been considered as an actionable drug target. However, pan-FGFR tyrosine …

The clinical role of liquid biopsy in oncology is growing significantly. In gliomas and other
brain tumours, targeted sequencing of cell-free DNA (cfDNA) from CSF may help differential …

Brain metastases (BM) is common in non-small-cell lung cancer (NSCLC) patients. Immune
checkpoint inhibitors (ICIs) have gradually become a routine treatment for NSCLC BM …

Simple Summary Brain metastases are the most common brain tumor in adults and are
associated with poor prognosis. The propensity of different solid tumors to metastasize …